Literature DB >> 7568032

Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.

Y Pommier1, G Kohlhagen, K W Kohn, F Leteurtre, M C Wani, M E Wall.   

Abstract

DNA topoisomerase I (top1) is a ubiquitous nuclear enzyme. It is specifically inhibited by camptothecin, a natural product derived from the bark of the tree Camptotheca acuminata. Camptothecin and several of its derivatives are presently in clinical trial and exhibit remarkable anticancer activity. The present study is a further investigation of the molecular interactions between the drug and the enzyme-DNA complex. We utilized an alkylating camptothecin derivative, 7-chloromethyl-10,11-methylenedioxycamptothecin (7-ClMe-MDO-CPT), and compared its activity against calf thymus top1 in a DNA oligonucleotide containing a single top1 cleavage site with the activity of its nonalkylating analog, 7-ethyl-10,11-methylenedioxycamptothecin (7-Et-MDO-CPT). In the presence of top1, 7-ClMe-MDO-CPT produced a DNA fragment that migrated more slowly than the top1-cleaved DNA fragment observed with 7-Et-MDO-CPT. Top1 was unable to religate this fragment in the presence of high NaCl concentration or proteinase K at 50 degrees C. This fragment was resistant to piperidine treatment and was also formed with an oligonucleotide containing a 7-deazaguanine at the 5' terminus of the top1-cleaved DNA (base + 1). It was however cleaved by formic acid treatment followed by piperidine. These observations are consistent with alkylation of the +1 base (adenine or guanine) by 7-ClMe-MDO-CPT in the presence of top1 covalent complexes and provide direct evidence that camptothecins inhibit top1 by binding at the enzyme-DNA interface.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568032      PMCID: PMC41067          DOI: 10.1073/pnas.92.19.8861

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative.

Authors:  P Fossé; B René; M Le Bret; C Paoletti; J M Saucier
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

2.  Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

Authors:  Y Pommier; G Capranico; A Orr; K W Kohn
Journal:  Nucleic Acids Res       Date:  1991-11-11       Impact factor: 16.971

Review 3.  DNA topoisomerases: why so many?

Authors:  J C Wang
Journal:  J Biol Chem       Date:  1991-04-15       Impact factor: 5.157

4.  New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site.

Authors:  J Q Svejstrup; K Christiansen; I I Gromova; A H Andersen; O Westergaard
Journal:  J Mol Biol       Date:  1991-12-05       Impact factor: 5.469

5.  Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

Authors:  G Capranico; K W Kohn; Y Pommier
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

6.  Structural modifications of camptothecin and effects on topoisomerase I inhibition.

Authors:  R T Crow; D M Crothers
Journal:  J Med Chem       Date:  1992-10-30       Impact factor: 7.446

7.  Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm.

Authors:  F Leteurtre; M Fesen; G Kohlhagen; K W Kohn; Y Pommier
Journal:  Biochemistry       Date:  1993-08-31       Impact factor: 3.162

8.  Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin.

Authors:  C Jaxel; G Capranico; D Kerrigan; K W Kohn; Y Pommier
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

9.  Chemical modification of an antitumor alkaloid camptothecin: synthesis and antitumor activity of 7-C-substituted camptothecins.

Authors:  S Sawada; K Nokata; T Furuta; T Yokokura; T Miyasaka
Journal:  Chem Pharm Bull (Tokyo)       Date:  1991-10       Impact factor: 1.645

Review 10.  The current status of camptothecin analogues as antitumor agents.

Authors:  W J Slichenmyer; E K Rowinsky; R C Donehower; S H Kaufmann
Journal:  J Natl Cancer Inst       Date:  1993-02-17       Impact factor: 13.506

View more
  19 in total

1.  Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.

Authors:  Y Takebayashi; P Pourquier; A Yoshida; G Kohlhagen; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

2.  Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.

Authors:  Y Pommier; G Kohlhagen; P Pourquier; J M Sayer; H Kroth; D M Jerina
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

3.  Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin.

Authors:  F Carrier; P T Georgel; P Pourquier; M Blake; H U Kontny; M J Antinore; M Gariboldi; T G Myers; J N Weinstein; Y Pommier; A J Fornace
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

4.  Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]- pyrene diol epoxide adducts at the 6-amino group of adenine.

Authors:  Y Pommier; G S Laco; G Kohlhagen; J M Sayer; H Kroth; D M Jerina
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

5.  Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites.

Authors:  Y Kwok; Q Zeng; L H Hurley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

6.  A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

7.  Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.

Authors:  N Vey; H Kantarjian; M Beran; S O'Brien; J Cortes; C Koller; E Estey
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

8.  A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin.

Authors:  Bradley A Hanson; Richard L Schowen; Valentino J Stella
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

Review 9.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes.

Authors:  Jaroslav Malina; Oldrich Vrana; Viktor Brabec
Journal:  Nucleic Acids Res       Date:  2009-07-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.